Handelsavisen
prelaunch
Companies Healthcare GBCS.PK
GB
GBCS.PK OTC Healthcare Providers & Services

Gbcs.Pk

$5,40
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-4,4 %
ROE
16,4 %
Net margin
-2,5 %
Debt / equity
-4,10
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

GBCS.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Business. GBCS.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Classification99 %
SectorHealth Care
Industry groupHealthcare Providers & Services
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
16,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GBCS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GBCS.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    GBCS.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Providers & Services
    AI synthesis
    GENERATED

    GBCS.PK exhibits a challenging capital structure, with a negative total equity of -$6,210,540 and a debt-to-equity ratio of -4.1, indicating a high reliance on debt financing. The company's liquidity position is further strained by a current ratio of 0.3, suggesting limited short-term liquidity to cover its liabilities. Despite a negative net income of -$1,015,750, the company reported positive operating cash flow of $1,882,030, which may provide some near-term liquidity support.

    Profitability metrics reveal a mixed picture. The company's return on equity is 16.36%, which is unusually high given the negative equity, and may not be a reliable indicator of performance. However, the return on assets is -3.12%, indicating that the company is not generating positive returns on its asset base. These figures suggest that the company is struggling to convert its assets into profitable operations, which is a concern in the healthcare services and equipment industry.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility and exposes the company to regional economic or regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets.

    Looking at the growth trajectory, the company's recent financial performance shows a decline in operating income, with a loss of $1,817,640. The capital expenditure of -$443,610 indicates a reduction in investment in long-term assets, which may affect future growth potential. The company's free cash flow is negative at -$23,440, suggesting that it is not generating sufficient cash to fund operations and growth without external financing.

    The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after accounting for total debt. The dilution risk is currently low, but the company's reliance on debt financing and negative equity could increase the likelihood of future dilution if additional capital is required. The company's financial structure and performance raise concerns about its ability to sustain operations and meet obligations without further financial restructuring.

    Recent events and filings indicate that the company has not disclosed any significant new developments or strategic initiatives. The lack of recent events or transcripts suggests limited public communication about the company's future plans or performance. This absence of information may indicate a lack of transparency or a focus on internal operations rather than public relations.

    Key takeaways
    • GBCS.PK has a negative equity position and a high debt-to-equity ratio, indicating a significant reliance on debt financing.
    • The company's liquidity position is weak, with a current ratio of 0.3 and a negative net cash position after debt.
    • Despite a high return on equity, the company's return on assets is negative, suggesting poor asset utilization.
    • The company's revenue is not diversified across segments or geographies, increasing its exposure to regional and operational risks.
    • The company's capital expenditure is negative, indicating a reduction in investment in long-term assets, which may affect future growth.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $5,40
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$6.2M
    Net cash
    -$24.4M
    Current ratio
    0.3
    Debt / equity
    -4.1
    ROA
    -3.1%
    ROE
    16.4%
    Cash conversion
    -185.0%
    CapEx / revenue
    -1.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryHealthcare Providers & Services16,0B node revenueOPCH 35,3%PACS 33,0%PRVA 13,3%SHC 7,3%NUTX 5,5%TOI 3,1%VMD 1,7%JYNT 0,3%Other 0,5%
    Source: company disclosures · own-taxonomy revenue-covered setGBCS 0,3% · rank #9 of 16

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs GBCS · multiples and returns
    OP
    OPCH
    Option Care Health Inc
    $22,09
    3,5B USD
    P/E
    16,5x
    vs self
    Div yield
    vs self
    ROE
    15,5 %
    vs self
    PA
    PACS
    Pacs Group Inc
    $38,00
    6,0B USD
    P/E
    25,2x
    vs self
    Div yield
    vs self
    ROE
    25,8 %
    vs self
    PR
    PRVA
    Privia Health Group Inc
    $23,90
    3,0B USD
    P/E
    123,6x
    vs self
    Div yield
    vs self
    ROE
    3,1 %
    vs self
    SH
    SHC
    Sotera Health Co
    $18,00
    5,1B USD
    P/E
    57,5x
    vs self
    Div yield
    vs self
    ROE
    12,9 %
    vs self
    NU
    NUTX
    NUTEX HEALTH INC.
    $176,00
    1,2B USD
    P/E
    9,7x
    vs self
    Div yield
    vs self
    ROE
    29,2 %
    vs self
    TO
    TOI
    Oncology Institute Inc
    $5,18
    527,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    372,2 %
    vs self
    VM
    VMD
    Viemed Healthcare Inc
    $11,00
    445,4M USD
    P/E
    26,7x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    vs self
    JY
    JYNT
    Joint Corp
    $8,21
    117,0M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -15,5 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-4,4 %Below median
    Net Margin-2,5 %Below median
    ROE16,4 %Above median
    Capex / Rev-1,1 %Below median
    D/E-4,10Best in class
    Cash Conv-1,85Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • GBCS.PK Market data — financials · 2026-05-28
    • Selectis Health Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    99shares short
    1days to cover
    189fails-to-deliver
    as of 2026-03-13 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GBCS.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 4.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 1,130.1%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 48.7%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 203.2%Derived (calculated)
    • Net margin (FY 2025-12-31): -2.5%Derived (calculated)
    • Return on equity (FY 2025-12-31): 16.4%Derived (calculated)
    • Return on assets (FY 2025-12-31): -3.1%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.30xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): -6.25xDerived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 42.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -0.2%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -29.9%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 58.1%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -2.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.5%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -14.8%Derived (calculated)
    • Long-term debt (annual): USD 13.41MSEC XBRL filing
    • Total assets (annual): USD 32.58MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Revenue (annual): USD 41.44MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Operating cash flow (annual): USD 1.88MSEC XBRL filing
    • Pre-tax income (annual): USD -1.01MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage